TICKERNERD
Menu
ODTXHealthcare · Biotechnology

ODTX Stock Forecast: Odyssey Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$25
−4.70% on the day

The 5 Wall Street analysts covering Odyssey Therapeutics, Inc. hold a median 12-month price target of $30 — +19.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.2B
Ticker Nerd rank
1 / 100
Median analyst target
$30
Analysts covering
5
Revenue$0.0−100.0% y/y
Operating income−$46.7M
Net income−$52.8M
Free cash flow−$34.7M
Quarterly, 6 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+20.6%
1M
+34.8%
From high
−4.7%
From low
+61.6%
$16
$26
Range since 8 May 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

ODTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Odyssey Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
43
Revisions
26
Momentum
18
Growth
8
Accruals
8
Value
7
Issuance
6
Quality
4
Volatility
3

Size (43): Smaller than most of the companies we track.

Volatility (3): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ODTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ODTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 8 May 2026Adjusted close, US dollars
$15$20$25$30$35$40Jun 26Jul 26Aug 26ODTXHigh $40Median $30Low $29

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $29Median $30High $40

The green dot is the last close — the median target sits +19.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026JP MorganMaintainsOverweight$26 → $29
18 June 2026OppenheimerReiteratesOutperform$40
18 June 2026OppenheimerReiteratesOutperform—
2 June 2026Cantor FitzgeraldInitiatesOverweight—
2 June 2026JP MorganInitiatesOverweight—
2 June 2026OppenheimerInitiatesOutperform—
2 June 2026TD CowenInitiatesBuy—
2 June 2026WedbushInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ODTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ODTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

ODTX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150160Jun 26Jul 26Aug 26ODTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ODTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Odyssey Therapeutics, Inc. (ODTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.6×

Cheaper than 89% of US stocks

Price / sales
12208.8×

Cheaper than 1% of US stocks

Price / book
2.9×

Cheaper than 35% of US stocks

EV / EBITDA
−6.1×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−156392.9%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
30.4%

Higher than 88% of US stocks

Return on assets
−55.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Odyssey Therapeutics, Inc. (ODTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Odyssey Therapeutics, Inc. has a market value of $1.2B and an enterprise value of $919.4M.

  • Revenue in the twelve months to 30 June 2026: $2.9M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$170.7M, a −5934.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−5.44.

  • Free cash flow in the twelve months to 30 June 2026: −$149.7M.

  • Shares outstanding: 48.0M.

  • Trailing P/E: −4.6×; forward P/E: −5.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Odyssey Therapeutics, Inc. employs 100 people — $29K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

ODTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ODTXOdyssey Therapeutics, Inc.$1.2B
1
OBXObsidian Therapeutics, Inc.$1.2B
62
MNKDMannKind Corp.$1.3B
34
CRVSCorvus Pharmaceuticals, Inc.$1.2B
54
GLUEMonte Rosa Therapeutics, Inc.$1.2B
59
SPTXSeaport Therapeutics, Inc.$1.3B
1
IMTXImmatics NV$1.2B
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Odyssey Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ODTX news & analysis

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

PRNewsWire · 6 Aug 2026positive

Evotec SE announced a strategic R&D collaboration with Odyssey Therapeutics to discover potential new treatments for autoimmune and inflammatory diseases. Under the agreement, Odyssey will use Evotec's data-driven discovery platform, advanced screening capabilities, and AI-enabled data science technologies to identify and validate small molecule drug candidates across multiple high-value disease targets.

Why it matters — The collaboration gives Odyssey access to Evotec's AI-enabled discovery platform and screening tools to support the advancement of its discovery-stage programs in high-need inflammatory and autoimmune diseases.

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 4 Aug 2026positive

Odyssey Therapeutics reported Q2 2026 financial results and a corporate update, noting $433.1M in cash on hand expected to fund operations into the second half of 2028. It also announced that Phase 2a monotherapy data for OD-001 was accepted for oral presentation at United European Gastroenterology Week in October, and that Phase 2a combination and Phase 2b monotherapy trials are expected to initiate in 2H 2026.

Why it matters — This update gives ODTX watchers visibility on a cash runway into the second half of 2028 and near-term catalysts for its lead candidate OD-001, including an upcoming data presentation and planned Phase 2a/Phase 2b trial initiations in 2026.

FAQ

Frequently asked questions about ODTX stock

What is the ODTX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Odyssey Therapeutics, Inc. have a median 12-month price target of $30, with estimates ranging from $29 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ODTX stock a buy right now?

Of the 5 analysts covering Odyssey Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Odyssey Therapeutics, Inc. 1 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ODTX?

As at 22 Aug 2026, Odyssey Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (43 of 100).

Will ODTX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +19.3% from the last close, and Ticker Nerd's factor model ranks Odyssey Therapeutics, Inc. 1 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ODTX stock forecast for 2030?

No analyst covering Odyssey Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ODTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $29 to $40 over the next 12 months.

What does Odyssey Therapeutics, Inc. do?

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune and inflammatory diseases.

What is the latest news on ODTX?

The most recent item we track (PRNewsWire, 6 Aug 2026): "Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases". Evotec SE announced a strategic R&D collaboration with Odyssey Therapeutics to discover potential new treatments for autoimmune and inflammatory diseases. Under the agreement, Odyssey will use Evotec's data-driven discovery platform, advanced screening capabilities, and AI-enabled data science technologies to identify and validate small molecule drug candidates across multiple high-value disease targets.

Company

About Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune and inflammatory diseases. The company advances a pipeline of small molecule and protein therapeutics that target upstream signaling nodes in the innate immune system to prevent pathological inflammation. Key programs include OD-001, an oral small molecule RIPK2 scaffolding inhibitor for ulcerative colitis and Crohn’s disease; OD-002, an SLC15A4 inhibitor for cutaneous lupus erythematosus, nephropathies, and B cell-mediated diseases; and OD-003, a TNFR2 agonist protein therapeutic for atopic dermatitis, systemic lupus erythematosus, and alopecia areata. Additional candidates address TSLP/IL-33 for asthma and COPD, IRAK4 scaffolding for atopic dermatitis and hidradenitis suppurativa, and IRF5 in collaboration with partners. Founded in 2021 and headquartered in the United States, Odyssey Therapeutics leverages expertise in immunology to create precise treatments that modulate inflammatory dysregulation, aiming to address significant unmet needs in immunology through selective targeting of disease-relevant pathways.

CEO Dr. Gary D. Glick Ph.D. · 100 employees · United States · https://odysseytx.com